NIKKEI 225
33,231.27 -200.24 (-0.60%) HANG SENG
16,646.05 -184.25 (-1.09%) CRUDE OIL
73.34 -0.73 (-0.99%) GOLD FUTURES
2,047.60 -42.10 (-2.01%) DOW
36,204.44 -41.06 (-0.11%) Bitcoin GBP
33,066.52 +1,683.72 (+5.37%)
Teva Pharmaceutical Industries Limited (0LER.IL)
| Previous close | 9.88 |
| Open | 9.75 |
| Bid | 9.02 x 0 |
| Ask | 10.45 x 0 |
| Day's range | 9.63 - 10.00 |
| 52-week range | 7.10 - 11.25 |
| Volume | |
| Avg. volume | 9,812 |
| Market cap | 13.463B |
| Beta (5Y monthly) | 1.15 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.90 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.22 |
Business WireTeva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
PARSIPPANY, N.J., November 30, 2023--Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today closing of its collaboration deal to co-develop and co-commercialize asset TEV ‘574 with Sanofi (EURONEXT: SAN and NASDAQ: SNY). TEV '574 is currently in Phase 2b clinical trials for the treatment of ulcerative colitis and Crohn's disease, two types of inflammatory bowel disease.
- Yahoo Finance Video
Teva Pharmaceutical upgraded to 'Buy' at UBS
UBS upgraded Teva Pharmaceutical (TEVA) to Buy from Neutral and raised its price target on the stock to $13 per share. UBS sees Teva "uniquely positioned to undergo a significant transition" to a more brand-focused company. Yahoo Finance anchors Seana Smith and Diane King Hall break down UBS's call on Teva and the stock's recent gains. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
